Aperio Group LLC boosted its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 12.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 442,197 shares of the medical research company’s stock after purchasing an additional 50,291 shares during the period. Aperio Group LLC owned about 0.06% of Amgen worth $76,898,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Jackson Grant Investment Advisers Inc. lifted its stake in Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares during the period. South Texas Money Management Ltd. increased its holdings in shares of Amgen by 0.7% in the second quarter. South Texas Money Management Ltd. now owns 3,223 shares of the medical research company’s stock valued at $555,000 after purchasing an additional 22 shares in the last quarter. Glenview Trust Co increased its holdings in shares of Amgen by 0.4% in the second quarter. Glenview Trust Co now owns 6,137 shares of the medical research company’s stock valued at $1,057,000 after purchasing an additional 25 shares in the last quarter. Roberts Glore & Co. Inc. IL increased its holdings in shares of Amgen by 0.4% in the second quarter. Roberts Glore & Co. Inc. IL now owns 7,425 shares of the medical research company’s stock valued at $1,279,000 after purchasing an additional 27 shares in the last quarter. Finally, Homrich & Berg increased its holdings in shares of Amgen by 2.1% in the second quarter. Homrich & Berg now owns 1,442 shares of the medical research company’s stock valued at $248,000 after purchasing an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 79.61% of the company’s stock.
A number of analysts recently weighed in on the stock. Mizuho raised their price target on shares of Amgen from $192.00 to $200.00 and gave the company a “buy” rating in a report on Monday, February 12th. Leerink Swann reissued a “market perform” rating on shares of Amgen in a report on Friday, February 2nd. Morgan Stanley lowered their price target on shares of Amgen from $204.00 to $196.00 and set an “overweight” rating for the company in a report on Friday, February 2nd. BMO Capital Markets raised their price target on shares of Amgen from $192.00 to $202.00 and gave the company a “market perform” rating in a report on Friday, February 2nd. Finally, JPMorgan Chase & Co. reissued a “hold” rating and issued a $191.00 price target on shares of Amgen in a report on Sunday, February 4th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $191.72.
In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total transaction of $283,070.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.19% of the company’s stock.
Shares of Amgen, Inc. (NASDAQ AMGN) opened at $189.75 on Friday. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. Amgen, Inc. has a fifty-two week low of $152.16 and a fifty-two week high of $201.23. The company has a market cap of $136,730.00, a price-to-earnings ratio of 17.25, a price-to-earnings-growth ratio of 2.33 and a beta of 1.37.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the prior year, the business earned $2.89 earnings per share. equities analysts forecast that Amgen, Inc. will post 13.24 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be given a dividend of $1.32 per share. The ex-dividend date is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.78%. Amgen’s dividend payout ratio is 48.00%.
Amgen declared that its Board of Directors has authorized a share repurchase program on Thursday, February 1st that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.
TRADEMARK VIOLATION NOTICE: “Aperio Group LLC Has $76.90 Million Holdings in Amgen, Inc. (AMGN)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/03/16/aperio-group-llc-has-76-90-million-holdings-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.